159 related articles for article (PubMed ID: 11844826)
1. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Harper-Wynne CL; Sacks NP; Shenton K; MacNeill FA; Sauven P; Laidlaw IJ; Rayter Z; Miall S; Howes A; Salter J; Hills MJ; Lowe FM; A'Hern R; Nasiri N; Doody D; Iqbal J; Dowsett M
J Clin Oncol; 2002 Feb; 20(4):1026-35. PubMed ID: 11844826
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
3. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Van Ginckel R; Janssens B; Callens M; Goeminne N; Wouters L; De Coster R
Cancer Chemother Pharmacol; 1996; 38(1):21-8. PubMed ID: 8603447
[TBL] [Abstract][Full Text] [Related]
4. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
[TBL] [Abstract][Full Text] [Related]
5. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
[TBL] [Abstract][Full Text] [Related]
6. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
7. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
9. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
11. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
12. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
13. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Harper-Wynne C; Ross G; Sacks N; Salter J; Nasiri N; Iqbal J; A'Hern R; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):614-21. PubMed ID: 12101108
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Goss PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S59-65; discussion S73-7. PubMed ID: 9797019
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
17. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Dowsett M; Doody D; Miall S; Howes A; English J; Coombes RC
Breast Cancer Res Treat; 1999 Jul; 56(1):25-34. PubMed ID: 10517340
[TBL] [Abstract][Full Text] [Related]
18. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Geisler J; Ekse D; Hösch S; Lønning PE
J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]